LIGAND PHARMACEUTICALS INCORPORATED Equity Securities, FV-NI, Realized Gain (Loss)
LIGAND PHARMACEUTICALS INCORPORATED (LGNDZ) reported Equity Securities, FV-NI, Realized Gain (Loss) of $60.00 million for the 9-month period ending 2024-09-30, per its 10-Q filed 2025-11-07.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiRealizedGainLoss · last filed 2025-11-07
- LIGAND PHARMACEUTICALS INCORPORATED equity securities, fv-ni, realized gain (loss) for the quarter ending 2024-09-30 was $0.00.
- LIGAND PHARMACEUTICALS INCORPORATED equity securities, fv-ni, realized gain (loss) for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- LIGAND PHARMACEUTICALS INCORPORATED equity securities, fv-ni, realized gain (loss) for the quarter ending 2024-03-31 was $60.00M, a 192.68% increase year-over-year.
- LIGAND PHARMACEUTICALS INCORPORATED equity securities, fv-ni, realized gain (loss) for the quarter ending 2023-09-30 was $0.00.
| Period end | Equity Securities, FV-NI, Realized Gain (Loss) 3 month | Equity Securities, FV-NI, Realized Gain (Loss) 6 month | Equity Securities, FV-NI, Realized Gain (Loss) 9 month |
|---|---|---|---|
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $0.00 derived: sum of 2 quarters · filed 2025-11-07 | $60.00M 10-Q · filed 2025-11-07 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $60.00M 10-Q · filed 2025-08-08 | |
| 2024-03-31 | $60.00M 10-Q · filed 2025-05-09 | ||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $16.60M derived: sum of 2 quarters · filed 2024-11-08 | $37.20M 10-Q · filed 2024-11-08 |
| 2023-06-30 | $16.60M 10-Q · filed 2023-08-09 | $37.20M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $20.50M 10-Q · filed 2023-05-08 |